Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Metformin and Empagliflozin in Insulin-Resistant HFrEF Patients
DRKS00013928Phase 2Recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and insulin resistance (IR) comparing Metformin + empagliflozin-placebo, Empagliflozin + metformin-placebo and Double placebo + standard care (3 arms). Started Jul 2018; status: recruiting.
02
Drugs
metforminempagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)insulin resistance (IR)
Beyond the preview
Go deeper on DRKS00013928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00013928.